Develops and commercializes solutions for sleep-disordered breathing conditions. Offers the Genio system, a hypoglossal neurostimulation therapy. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 85% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 13.3× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 15% of them.
Analysts' average target sits 165% above today's price.
An investor who bought at the very peak is down 95% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 4 years, sales grew about 85% a year on average.
Sales run at $11.6M a year. A small number, but proof the product has real buyers.
A loss of $104.5M against $11.6M in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, NYXH sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: NYXH is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (15/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.